Feature|Articles|December 26, 2023

Top 5 AI Stories of 2023

Author(s)Mike Hollan

As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.

The Promise and Challenges of Generative AI in Healthcare

Pharma industry stakeholders must develop actionable roadmaps to prioritize the areas in which the use of generative artificial intelligence can create the greatest benefits.

Embracing AI: Q&A with Shalu Chadha

Accenture’s global life sciences technology lead discusses how the life sciences industry has embraced artificial intelligence.

AI and Drug 'Re-Innovation'

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.

Harnessing AI for Pharma Sales

Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.

Data, AI, and the New Era of Field Teams: Q&A with Paul Shawah, executive vice president of commercial strategy at Veeva

Setting up a field team for the future necessitates equipping it with a toolbox of cutting-edge technological advancements. These tools enable the team to swiftly acquire essential, accurate information, as collectively advocated by biopharma organizations at Veeva's May 2023 Commercial Summit. Senior editor Fran Pollaro spoke with Paul Shawah, Veeva's executive vice president of commercial strategy, about the roles of data, ChatGPT, and AI in introducing new medicines to the market.

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.